MedPath

The effect of compound Ma-ol-asal on treatment of the pediatric asthma

Not Applicable
Completed
Conditions
Asthma.
Asthma
Registration Number
IRCT2015083123834N1
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
80
Inclusion Criteria

patients with asthma aged 6-16 years old that referred to the pulmonary clinic of the Mofid Children's Hospital, Tehran, Iran; patients who are willing and consent to participate in the study.
Exclusion criteria: Patients under 6 and over 16 yearsold; patients with modprate asthma; patients with severe asthma; patients requiring hospitalization and patients who have attack; patients with underlying diseases such as CF, Bronchopulmonary dysplasia, heart failure, bronchotracheomalacia, GERD, bronchiectasis, Pulmonary embolism and sarcoidosis; patients who are taking medications such as aspirin, beta blocker and NSAID's; patients who become affected to other acute disease during the study; patients who are allergic to any components of compound Ma-ol-asal and request and patients who have decision to excluded from the study.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath